39 results about "Antiretroviral therapy" patented technology

The present invention relates to a nutritional product for HIV patients that are not on Highly Active Antiretroviral Therapy. More specifically the invention relates to a nutritional composition comprising oligosaccharides. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.

The invention encompasses neutral dithiocarbamate metal compounds and methods of treating cancer using such compounds, along with methods for sensitizing AIDS/HIV patients to anti-retroviral therapy by blocking the P-glycoprotein membrane toxin extrusion pump using such compounds. Compounds inhibit the growth of cancer cells of a variety of cell types. A method is presented for using the neutral compounds disclosed herein, amongst other uses disclosed herein, to reduce tumor growth, and to potentiate the effect of other anticancer agents. The invention also encompasses pharmaceutical compositions comprising the neutral compounds and a pharmaceutically acceptable excipient, diluent, solubilizer, solvent, adjuvant or carrier, or a mixture thereof.

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

The invention includes methods of treating HIV infection in a patient where the method includes administration of an antibody to TNF-alpha and an antibody to interferon-gamma to the patient and administering antiretroviral therapy to a patient. The invention further includes methods of treating HIV infection in a patient where the method comprises administration of an antibody to TNF-alpha and an antibody to alpha interferon to the patient and administering antiretroviral therapy to a patient. The invention further includes a method of treating HIV infection in a patient where the method includes administering an antibody to alpha interferon and antiretroviral therapy to a patient. The invention further includes a method of treating an HIV infection in a patient where the method comprises administering a chimeric TNF-alpha receptor and anti-retroviral therapy to a patient.

The present invention discloses one kind of medicine composition for preventing and treating AIDS and its preparation process and use. The medicine composition consists of active ingredient and auxiliary ingredient, and may be prepared into granule, tablet, capsule, oral liquid or injection. It has the functions of inhibiting the copying of HIV, promoting immunologic reconstruction of the AIDS patient, delaying disease and clinical complication, and synergizing and attenuating in high efficiency retrovirus resisting therapy. The present invention has wide application foreground.

A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.

The present invention relates to antiviral drug susceptibility and resistance assays for identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), and to monitoring the clinical progression of HIV infection and Modes and methods of HIV infection response to antiretroviral therapy, in particular nucleoside reverse transcriptase inhibitor therapy using phenotypic sensitivity analysis and genotypic analysis.

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N¹N²CGN³N⁴, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.

The invention discloses a hepatitis B virus affinity adsorption column and a preparation method thereof, and relates to blood perfusion technology. The adsorption column comprises affinity microspheres (1), a polyester column (2) and separation membranes (3), wherein the polyester column (2) is filled with the affinity microspheres (1); and the two ends of the polyester column (2) are sealed by using the separation membranes (3). The method comprises the following steps of: (1) preparing adsorption microspheres; (2) activating the adsorption microspheres to obtain activated microspheres; (3) fixing an anti-body to obtain the affinity microspheres; (4) sealing unreacted aldehyde groups and epoxy groups; (5) filling the column; and (6) sealing membranes. The hepatitis B virus affinity adsorption column can assist or replace antiretroviral therapy of hepatitis B, has a remarkable effect, is suitable for clearing hepatitis B virus in the blood of a hepatitis B virus carrier, a patient with chronic hepatitis B, a patient with severe hepatitis B and a patient with liver cancer, and fulfills the aims of remission, treatment and saving the lives of patients.

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

The invention relates to traditional Chinese medicine capsule for treating bone marrow suppression caused by an highly active antiretroviral therapy (HAART) for AIDS (acquired immure deficiency syndrome), which effectively solves the treatment medication problem of the bone marrow suppression caused by the HAART for the AIDS, wherein the capsule is prepared by ginseng, angelica, fructus ligustri lucidi, caulis spatholobi, radix astragali, herba epimedii, pericarpium citri reticulatae and oldenlandia diffusa, wherein the angelica and the pericarpium citri reticulatae are crushed, added with the water and distilled to respectively collect essential oil and distilled water solution; the dregs of the angelica and the pericarpium citri reticulatae are mixed with the fructus ligustri lucidi, the caulis spatholobi, the radix astragali, the herba epimedii and the oldenlandia diffusa, and the mixture is added with water to decoct twice; during the decocting process, the decocting liquid is combined with the distilled water solution of the angelica and the pericarpium citri reticulatae; the mixture is filtered, condensed and added with the ginseng powder for evenly mixing; then the mixture is dried, crushed into fine powder and sieved; the essential oil of the angelica and the pericarpium citri reticulatae is injected and mixed uniformly, and the capsule is filled. The traditional Chinese medicine capsule in the invention have scientific prescription and good edible effect, can effectively solve the treatment medication problem of the bone marrow suppression caused by the HAART for the AIDS, and are innovation of the traditional Chinese medicine.

This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-specific subunit (e.g., ARID1A) to prevent nucleosomal positioning, relieving transcriptional repression of HIV-1. The subject methods can provide for reversal of latency of HIV-1 in cells in vitro or in vivo. Use of the macrolactam BAF complex modulating compounds represent a method of HIV latency reversal with a unique mechanism of action, which can be optionally combined with other Latency Reversal Agents to improve reservoir targeting. The subject methods can be utilized in conjunction with any convenient methods of treating HIV or HIV latency, including methods related to immune system activation, antiretroviral therapies and/or anti-HIV agents.

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodificiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

The present invention concerns small chemical compounds—Isatin and its derivatives, and a novel, safer and more convenient methods for the treatment of anemia resulting from various underlying conditions or diseases. The invention provides new methods to stimulate red cell production, and the new methods to prevent the development of anemia. The invention provides a new therapeutic approach for the treatment of chronic anemia patients, anemia patients who are receiving bone marrow suppressive therapies, HIV/AIDS patients who develop anemia upon the treatment of anti-retroviral therapies or from underlying disease itself, and anemia with other causes. The invention also provides methods for preventing anemia in many relatively healthy people such as young women who loss blood from menstrual blood.